Genetic variation in the renin-angiotensin system, use of renin-angiotensin system inhibitors and the risk of myocardial infarction

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 12, Issue 3, 2011, Pages 208-214

  Maitland Van Der Zee, Anke Hilse ^a   Van Wieren De Wijer, Diane B M A ^a,b   De Boer, Anthonius ^a   Kroon, Abraham A ^c   De Leeuw, Peter W ^c   Schiffers, Paul ^c   Janssen, Rob G J H ^d   Psaty, Bruce M ^e   Van Duijn, Cornelia M ^b   Stricker, Bruno H Ch ^b   Klungel, Olaf H ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibitors; ACE polymorphism; angiotensin II type 1 receptor antagonists; angiotensin II type 1 receptor polymorphism; angiotensinogen polymorphism; myocardial infarction; pharmacogenetics

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN; ZOFENOPRIL;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG USE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THERAPY EFFECT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 80052366086     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320310391834     Document Type: Article

References (26)

1. Klungel OH, Stricker BH, Paes AH, Seidell JC, Bakker A., Voko Z. et al. Excess stroke among hypertensive men and women attributable to undertreatment of hypertension. Stroke 1999 ; 30: 1312-1318. (Pubitemid 29296055)
2. Saunders E., Weir MR, Kong BW, Hollifield J., Gray J., Vertes V. et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990 ; 150: 1707-1713. (Pubitemid 20240985)
3. Schelleman H., Klungel OH, Witteman JC, Breteler MM, Hofman A., van Duijn CM et al. Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke. Pharmacogenomics J 2008 ; 8: 400-407.
4. Weir MR Providing end-organ protection with renin- angiotensin system inhibition: the evidence so far. J Clin Hypertens (Greenwich) 2006 ; 8: 99-105 ; quiz 106-107.
5. Psaty BM, Lumley T., Furberg CD, Schellenbaum G., Pahor M., Alderman MH et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003 ; 289: 2534-2544. (Pubitemid 37430155)
6. Schelleman H., Stricker BH, De Boer A., Kroon AA, Verschuren MW, Van Duijn CM et al. Drug-gene interactions between genetic polymorphisms and antihypertensive therapy. Drugs 2004 ; 64: 1801-1816. (Pubitemid 39215190)
7. Brugts JJ, Danser AH, de Maat MP, den Uil CA, Boersma E., Ferrari R. et al. Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy. Curr Opin Cardiol 2008 ; 23: 296-301. (Pubitemid 351787092)
8. Mondorf UF, Russ A., Wiesemann A., Herrero M., Oremek G. and Lenz T. Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension. Am J Hypertens 1998 ; 11: 174-183. (Pubitemid 28137608)
9. Todd GP, Chadwick IG, Higgins KS, Yeo WW, Jackson PR and Ramsay LE Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects. Br J Clin Pharmacol 1995 ; 39: 131-134.
10. Sasaki M., Oki T., Iuchi A., Tabata T., Yamada H., Manabe K. et al. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies. J Hypertens 1996 ; 14: 1403-1408.
11. Kohno M., Yokokawa K., Minami M., Kano H., Yasunari K., Hanehira T. et al. Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am J Med 1999 ; 106: 544-549. (Pubitemid 29231105)
12. Ohmichi N., Iwai N., Uchida Y., Shichiri G., Nakamura Y. and Kinoshita M. Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am J Hypertens 1997 ; 10: 951-955.
13. Miller JA, Thai K. and Scholey JW Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int 1999 ; 56: 2173-2180. (Pubitemid 30004746)
14. Schunkert H., Hense HW, Gimenez-Roqueplo AP, Stieber J., Keil U., Riegger GA et al. The angiotensinogen T235 variant and the use of antihypertensive drugs in a population-based cohort. Hypertension 1997 ; 29: 628-633. (Pubitemid 27074729)
15. Jeunemaitre X. Genetics of the human renin angiotensin system. J Mol Med 2008 ; 86: 637-641.
16. Spiering W., Kroon AA, Fuss-Lejeune MM, Daemen MJ and de Leeuw PW Angiotensin II sensitivity is associated with the angiotensin II type 1 receptor A(1166)C polymorphism in essential hypertensives on a high sodium diet. Hypertension 2000 ; 36: 411-416.
17. Jastrzebskal M., Widecka K., Naruszewicz M., Ciechanowicz A., Janczak- Bazan A., Foltynska A. et al. Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms. Nutr Metab Cardiovasc Dis 2004 ; 14: 259-269. (Pubitemid 39611868)
18. Bleumink GS, Schut AF, Sturkenboom MC, van Duijn CM, Deckers JW, Hofman A. et al. Mortality in patients with hypertension on angiotensin-I converting enzyme (ACE)-inhibitor treatment is influenced by the ACE insertion/ deletion polymorphism. Pharmacogenet Genom 2005 ; 15: 75-81. (Pubitemid 40562984)
19. Voors AA, van Geel PP, Oosterga M., Buikema H., van Veldhuisen DJ and van Gilst WH Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism. J Renin Angiotensin Aldosterone Syst 2004 ; 5: 130-134. (Pubitemid 39406721)
20. Arnett DK, Davis BR, Ford CE, Boerwinkle E., Leiendecker-Foster C., Miller MB et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension- Associated Treatment (GenHAT) study. Circulation 2005 ; 111: 3374-3383. (Pubitemid 40923390)
21. van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A., Stricker BH, Kroon AA, de Leeuw PW et al. Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment. Pharm World Sci 2009 ; 31: 158-164.
22. WHO Collaborating Centre for Drug Statistics: Methodology about the ATC/DDD system http://www.whocc.no/atcddd/atcsystem.html (accessed 16 November 2008 ).
23. Knaapen AM, Ketelslegers HB, Gottschalk RW, Janssen RG, Paulussen AD, Smeets HJ et al. Simultaneous genotyping of nine polymorphisms in xenobiotic-metabolizing enzymes by multiplex PCR amplification and single base extension. Clin Chem 2004 ; 50: 1664-1668. (Pubitemid 39121237)
24. Bozkurt O., Verschuren WM, van Wieren-de Wijer BM, Knol MJ, de Boer A., Grobbee DE et al. Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives. J Hum Hypertens 2008 ; 22: 774-780.
25. Bis JC, Smith NL, Psaty BM, Heckbert SR, Edwards KL, Lemaitre RN et al. Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients. Am J Hypertens 2003 ; 16: 1011-1017. (Pubitemid 37500795)
26. Schelleman H., Klungel OH, Witteman JC, Breteler MM, Yazdanpanah M., Danser AH et al. Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers. Eur J Hum Genet 2007 ; 15: 478-484. (Pubitemid 46487703)